LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

PetIQ to Participate in the Oppenheimer 24th Annual Consumer Growth and E-Commerce Conference

June 05, 2024 | Last Trade: US$30.75 0.01 0.03

EAGLE, Idaho, June 05, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, product and wellness company, today announced that members of its executive management team will participate in the Oppenheimer 24th Annual Consumer Growth and E-Commerce Conference. A virtual fireside chat will be available on Tuesday, June 11, 2024 at 10:30 a.m. EDT. The live webcast and replay is accessible on the “Investors” section of the Company’s website at www.PetIQ.com.

About PetIQ

PetIQ is a leading pet medication, health and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable products and veterinary services. The Company's product business engages with pet parents through retail and e-commerce sales channels with its branded and distributed pet medications as well as health and wellness items. PetIQ manufactures and distributes pet products from its world-class facilities in Omaha, Nebraska, Springville, Utah and Daytona Beach, Florida. The Company’s veterinarian services offering operates in over 2,600 mobile community clinic locations and wellness centers hosted at retail partners in 39 states. PetIQ believes that pets are an important part of the family and deserve the best products and care we can provide them.

Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.  or 208.513.1513
Media: This email address is being protected from spambots. You need JavaScript enabled to view it. or 407.929.6727


Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB